Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Level 1 - systematic review of randomized trials
Pooled analysis of 9 randomized clinical trials
PubMed 16266753 · doi:10.1016/j.jad.2005.09.003
What was done
Researchers pooled and analyzed data from 9 clinical trials assessing duloxetine efficacy and safety for major depressive disorder. They examined the incidence, severity, resolution time, and dose-dependency of discontinuation-emergent adverse events (DEAEs) following abrupt treatment cessation across 6 short-term trials and 3 long-term studies.
What was found
In the short-term trials, DEAEs occurred in 44.3% of duloxetine-treated patients versus 22.9% of placebo-treated patients (p < 0.05). Duloxetine patients reporting DEAEs had a mean of 2.4 symptoms. Discontinuation events significantly higher on duloxetine than placebo included dizziness (12.4%), nausea (5.9%), headache (5.3%), paresthesia (2.9%), vomiting (2.4%), irritability (2.4%), and nightmares (2.0%). Dizziness was also the most frequent DEAE across the long-term studies. Most events were mild or moderate in severity; 45.1% resolved by study endpoint, with 65.0% of resolved cases subsiding within 7 days. DEAE rates were highest at 120 mg/day, and all doses between 40 and 120 mg/day significantly exceeded placebo. Treatment duration beyond 8 to 9 weeks was not associated with increased DEAE incidence or severity.
Why it matters
This paper characterizes the withdrawal profile of duloxetine, demonstrating that abrupt cessation causes common discontinuation symptoms comparable to other SSRIs and SNRIs. The findings support clinical recommendations to taper duloxetine over at least 2 weeks rather than stopping abruptly.
Limits
Total participant count (n) is not provided in the abstract. Adverse events were captured via spontaneous reporting rather than systematic discontinuation scales, which can underestimate true incidence. More than half (54.9%) of reported DEAEs had not resolved by the end of the study observation periods.
Cited by
- supports Discontinuing Cymbalta (duloxetine) causes sensations of electric shocks ("the jolts").